Hint of minor added benefit for Bayer's Stivarga seen by IQWiG

13 January 2014

There was a hint of positive news for German drug major Bayer (BAYN: DE), when the German Institute for Quality and Efficiency in Health Care (IQWiG) announced that, following an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG), it has concluded that the company’s cancer drug Stivarga (regorafenib) offers an added benefit over the appropriate comparator therapy specified by the Federal Joint Committee (G-BA).

According to the findings, there is a hint of a minor added benefit of regorafenib. Patients have a survival advantage, but certain severe side effects occur more frequently.

Stivarga was approved in the European Union last year for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have previously been treated with, or are not considered candidates for, available therapies (The Pharma Letter August 30, 2013. The drug, which is was approved in the USA in 2012 and is still rolling out in markets, has been touted as having a blockbuster sales potential for Bayer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK